Ignacio Faus
Fortuna: 12 400 $ al 31/05/2026
Fortuna: 12 400 $ al 31/05/2026
Ignacio Faus was the founder of Palau Pharma SA, serving as Chief Executive Officer from 2006 to 2013.
Dr. Faus is the founder of NFL Biosciences SAS, holding the title of Director & Managing Director since 2024.
Dr. Faus is the founder of DRI Healthcare, serving as Advisor.
Former positions include Chief Executive Officer at Mologen AG from 2018 to 2019, Chief Executive Officer & Director at Genmedica Therapeutics SL, Executive Director at Sage Healthcare Ltd., and Manager-Business Development at Noucor Health SA from 1993 to 2006.
Education includes a doctorate from Indiana University conferred in 1998 and an MBA from Kellogg School of Management conferred in 1993.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
DRI Healthcare Trust
DRI Healthcare Trust Investment Trusts/Mutual FundsMiscellaneous Operates as a royalty trust 0 % | 13/11/2025 | 1.000 ( 0 % ) | 12 400 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| NFL BIOSCIENCES | Director/Miembro de la Junta | 17/10/2024 |
DRI Healthcare
DRI Healthcare Investment ManagersFinance DRI Healthcare invests in royalty interests in leading pharmaceutical and biotechnology companies, research institutions, universities and inventors. | Consultor / Asesor | - |
| Empresas | Cargo | Fin |
|---|---|---|
| MOLOGEN AG | Director Ejecutivo | 31/03/2019 |
Palau Pharma SA
Palau Pharma SA BiotechnologyHealth Technology Provides research and development services to the pharmaceutical sector | Director Ejecutivo | 01/01/2013 |
Noucor Health SA
Noucor Health SA Miscellaneous Commercial ServicesCommercial Services Engages in research, development and manufacturing of medicines & food supplements | Corporate Officer/Principal | 01/11/2006 |
Sage Healthcare Ltd.
Sage Healthcare Ltd. Miscellaneous Commercial ServicesCommercial Services Provides management consulting services to the healthcare industry | Director/Miembro de la Junta | - |
Genmedica Therapeutics SL
Genmedica Therapeutics SL BiotechnologyHealth Technology Engages in the research and development of treatments for metabolic disorders | Director Ejecutivo | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 9 |
|---|---|
DRI Healthcare
DRI Healthcare Investment ManagersFinance DRI Healthcare invests in royalty interests in leading pharmaceutical and biotechnology companies, research institutions, universities and inventors. | Finance |
MOLOGEN AG
MOLOGEN AG Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops immunotherapies for the treatment of infectious diseases | Health Technology |
Indiana University
Indiana University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Noucor Health SA
Noucor Health SA Miscellaneous Commercial ServicesCommercial Services Engages in research, development and manufacturing of medicines & food supplements | Commercial Services |
Genmedica Therapeutics SL
Genmedica Therapeutics SL BiotechnologyHealth Technology Engages in the research and development of treatments for metabolic disorders | Health Technology |
Palau Pharma SA
Palau Pharma SA BiotechnologyHealth Technology Provides research and development services to the pharmaceutical sector | Health Technology |
Sage Healthcare Ltd.
Sage Healthcare Ltd. Miscellaneous Commercial ServicesCommercial Services Provides management consulting services to the healthcare industry | Commercial Services |
Kellogg School of Management
Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NFL Biosciences SAS
NFL Biosciences SAS BiotechnologyHealth Technology Operates as a biotechnology company that develops botanical treatments for addictions | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.